EU, AstraZeneca reach deal to end vaccine delivery dispute

The European Commission said the commitment involves the pharmaceutical company providing 135 million doses by the end of this year, plus another 65 million doses in the first quarter of 2022

September 03, 2021 04:46 pm | Updated 04:46 pm IST - Brussels

Illustration picture. File

Illustration picture. File

The European Union says it has reached an agreement with drugmaker AstraZeneca to end their legal battle over the slow delivery of the Anglo-Swedish company's coronavirus vaccine.

The EU's executive branch, the European Commission, said on Friday that AstraZeneca made a “firm commitment” to deliver a total of 300 million vaccine doses by March next year.

The commission said it involves the pharmaceutical company providing 135 million doses by the end of this year, plus another 65 million doses in the first quarter of 2022.

Brussels said the deliveries would respect an advance purchasing agreement the EU reached with AstraZeneca a year ago. Tens of millions of doses already have been supplied to EU member nations, but not as many as the 27-nation bloc expected.

A Belgian court ruled in June that AstraZeneca had committed a “serious breach” of its contract with the EU. But the company said the ruling showed that “AstraZeneca has fully complied with its agreement” with the European Commission.

AstraZeneca was seen as a key pillar of the EU's vaccine rollout. The legal tussle over delivery obligations tarnished the company's image, but the commission has no issue with the quality of the firm's vaccines.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.